Table 2.

Clinical characteristics during follow-up of all cancer patients subjected to one or several ActiGraph registrations at home (4-5 d)

GroupFollow-up period (mo)
048>12
Total number of patients at risk53382513
    ActiGraph registrations39291522
Age71 ± 270 ± 267 ± 261 ± 1
Male/female28/1120/910/514/8
Weight (kg)70 ± 270 ± 270 ± 468 ± 2
Weight loss (%)11 ± 113 ± 214 ± 213 ± 2
Hemoglobin concentration (g/L)125 ± 2124 ± 2126 ± 4129 ± 2
ESR (mm/h)35 ± 334 ± 529 ± 516 ± 2
CRP (mg/L)20 ± 524 ± 732 ± 127 ± 1
Serum creatinine (μmol/L)89 ± 583 ± 573 ± 574 ± 3
Serum calcium (mmol/L)2.3 ± 0.022.3 ± 0.022.3 ± 0.032.3 ± 0.02
Serum ASAT (μkat/L)0.6 ± 0.070.6 ± 0.080.9 ± 0.20.6 ± 0.06
Serum ALAT (μkat/L)0.6 ± 0.110.5 ± 0.060.9 ± 0.30.5 ± 0.08
ALP (μkat/L)2.4 ± 0.22.5 ± 0.32.9 ± 0.42.2 ± 0.5
Serum bilirubin (μmol/L)14 ± 213 ± 217 ± 413 ± 2
CEA551 ± 3441423 ± 851723 ± 498416 ± 410
CA 12595 ± 20120 ± 38310 ± 15797 ± 37
CA 19-91,022 ± 3262,576 ± 14273,905 ± 1601184 ± 155
  • NOTE: Tumor markers: CEA, CA-125, and CA 19-9 (normal values, <30, <5, and <25, respectively). ESR (normal values: <20 for females, <28 for male). CRP (normal value, <5). Liver function tests: serum bilirubin, alkaline phosphatase (ALP), aspartate amino transferase (ASAT), and alanine amino transferase (ALAT; normal values, <5, <1.8, <0.75, and <1.1, respectively). Mean ± SE.